Literature DB >> 21862698

Cigarette smoking, obesity, physical activity, and alcohol use as predictors of chemoprevention adherence in the National Surgical Adjuvant Breast and Bowel Project P-1 Breast Cancer Prevention Trial.

Stephanie R Land1, Walter M Cronin, D Lawrence Wickerham, Joseph P Costantino, Nicholas J Christian, William M P Klein, Patricia A Ganz.   

Abstract

The double-blind, prospective, National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial (BCPT) showed a 50% reduction in the risk of breast cancer for tamoxifen versus placebo, yet many women at risk of breast cancer do not adhere to the 5-year course. This first report of the rich BCPT drug adherence data examines predictors of adherence. Between June, 1992 and September, 1997 13,338 women at high risk of breast cancer were randomly assigned to 20 mg/d tamoxifen versus placebo; we analyzed the 11,064 enrolled more than 3 years before trial unblinding. Primary endpoint was full drug adherence (100% of assigned pills per staff report, excluding protocol-required discontinuation) at 1 and 36 months; secondary was adequate adherence (76%-100%). Protocol-specified multivariable logistic regression tested lifestyle factors, controlling for demographic and medical predictors. About 13% were current smokers; 60% were overweight/obese; 46% had moderate/heavy physical activity; 21%, 66%, 13% drank 0, 0-1, 1+ drinks per day, respectively; 91% were adequately adherent at 1 month; and 79% were at 3 years. Alcohol use was associated with reduced full adherence at 1 month (P = 0.016; OR = 0.79 1+ vs. 0), as was college education (P <0.001; OR = 0.78 vs. high school); age (P < 0.001; OR = 1.4 age 60+) and per capita household annual income (P < 0.001; OR = 1.2 per $30,000) with increased adherence. Current smoking (P = 0.003; OR = 0.75), age (P = 0.024, OR = 1.1), college education (P = 0.037; OR = 1.4), tamoxifen assignment (P = 0.031; OR = 0.84), and breast cancer risk (P <.001; OR = 1.5 high vs. low) predicted adequate adherence at 36 months. There were no significant associations with obesity or physical activity. Alcohol use and smoking might indicate a need for greater adherence support. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21862698      PMCID: PMC3180877          DOI: 10.1158/1940-6207.CAPR-11-0172

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  39 in total

1.  Tamoxifen non-compliance: does it matter?

Authors:  Vedang Murthy; Geeta Bharia; Rajiv Sarin
Journal:  Lancet Oncol       Date:  2002-11       Impact factor: 41.316

2.  Adherence to a breast cancer screening program and its predictors in underserved women in southern Brazil.

Authors:  Maira Caleffi; Rodrigo A Ribeiro; Ademar J Bedin; Júlia M P Viegas-Butzke; Fernanda D G Baldisserotto; Giovana P Skonieski; Juliana Giacomazzi; Suzi A Camey; Patrícia Ashton-Prolla
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-08-17       Impact factor: 4.254

Review 3.  Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer.

Authors:  M H Gail; J P Costantino; J Bryant; R Croyle; L Freedman; K Helzlsouer; V Vogel
Journal:  J Natl Cancer Inst       Date:  1999-11-03       Impact factor: 13.506

4.  Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women.

Authors:  S Demissie; R A Silliman; T L Lash
Journal:  J Clin Oncol       Date:  2001-01-15       Impact factor: 44.544

5.  Stigma as a barrier to recovery: Perceived stigma and patient-rated severity of illness as predictors of antidepressant drug adherence.

Authors:  J A Sirey; M L Bruce; G S Alexopoulos; D A Perlick; S J Friedman; B S Meyers
Journal:  Psychiatr Serv       Date:  2001-12       Impact factor: 3.084

6.  Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer.

Authors:  Ann H Partridge; Philip S Wang; Eric P Winer; Jerry Avorn
Journal:  J Clin Oncol       Date:  2003-02-15       Impact factor: 44.544

7.  Correlation between tamoxifen elimination and biomarker recovery in a primary prevention trial.

Authors:  A Guerrieri-Gonzaga; L Baglietto; H Johansson; B Bonanni; C Robertson; M T Sandri; L Canigiula; C Lampreda; S Diani; E A Lien; A Decensi
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2001-09       Impact factor: 4.254

8.  Duration of adjuvant tamoxifen therapy.

Authors:  J Bryant; B Fisher; J Dignam
Journal:  J Natl Cancer Inst Monogr       Date:  2001

9.  Associations of body mass index and obesity with physical activity, food choices, alcohol intake, and smoking in the 1982-1997 FINRISK Studies.

Authors:  Marjaana Lahti-Koski; Pirjo Pietinen; Markku Heliövaara; Erkki Vartiainen
Journal:  Am J Clin Nutr       Date:  2002-05       Impact factor: 7.045

10.  Clinical pharmacology of tamoxifen in patients with breast cancer: correlation with clinical data.

Authors:  C Fabian; L Sternson; M El-Serafi; L Cain; E Hearne
Journal:  Cancer       Date:  1981-08-15       Impact factor: 6.860

View more
  29 in total

1.  Body mass index and the risk for developing invasive breast cancer among high-risk women in NSABP P-1 and STAR breast cancer prevention trials.

Authors:  Reena S Cecchini; Joseph P Costantino; Jane A Cauley; Walter M Cronin; D Lawrence Wickerham; Stephanie R Land; Joel L Weissfeld; Norman Wolmark
Journal:  Cancer Prev Res (Phila)       Date:  2012-02-07

2.  Chemoprevention Uptake among Women with Atypical Hyperplasia and Lobular and Ductal Carcinoma In Situ.

Authors:  Meghna S Trivedi; Austin M Coe; Alejandro Vanegas; Rita Kukafka; Katherine D Crew
Journal:  Cancer Prev Res (Phila)       Date:  2017-06-13

3.  Cigarette smoking, physical activity, and alcohol consumption as predictors of cancer incidence among women at high risk of breast cancer in the NSABP P-1 trial.

Authors:  Stephanie R Land; Qing Liu; D Lawrence Wickerham; Joseph P Costantino; Patricia A Ganz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-02-25       Impact factor: 4.254

4.  Addressing barriers to uptake of breast cancer chemoprevention for patients and providers.

Authors:  Katherine D Crew
Journal:  Am Soc Clin Oncol Educ Book       Date:  2015

5.  Integrating knowledge across domains to advance the science of health behavior: overcoming challenges and facilitating success.

Authors:  William M P Klein; Emily G Grenen; Mary O'Connell; Danielle Blanch-Hartigan; Wen-Ying Sylvia Chou; Kara L Hall; Jennifer M Taber; Amanda L Vogel
Journal:  Transl Behav Med       Date:  2017-03       Impact factor: 3.046

6.  How do we safely get people to stop smoking?

Authors:  David C L Lam; John D Minna
Journal:  Cancer Prev Res (Phila)       Date:  2011-11

7.  Acceptance and adherence to chemoprevention among women at increased risk of breast cancer.

Authors:  Richard G Roetzheim; Ji-Hyun Lee; William Fulp; Elizabeth Matos Gomez; Elissa Clayton; Sharon Tollin; Nazanin Khakpour; Christine Laronga; Marie Catherine Lee; John V Kiluk
Journal:  Breast       Date:  2014-12-06       Impact factor: 4.380

8.  Symptoms and QOL as Predictors of Chemoprevention Adherence in NRG Oncology/NSABP Trial P-1.

Authors:  Stephanie R Land; Farzana L Walcott; Qing Liu; D Lawrence Wickerham; Joseph P Costantino; Patricia A Ganz
Journal:  J Natl Cancer Inst       Date:  2015-11-27       Impact factor: 13.506

9.  Discontinuation and non-adherence to endocrine therapy in breast cancer patients: is lack of communication the decisive factor?

Authors:  P Wuensch; A Hahne; R Haidinger; K Meißler; B Tenter; C Stoll; B Senf; J Huebner
Journal:  J Cancer Res Clin Oncol       Date:  2014-08-02       Impact factor: 4.553

10.  Non-compliance with the initial screening exam visit in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.

Authors:  Pamela M Marcus; Sheryl L Ogden; Lisa H Gren; Jeffery C Childs; Shannon M Pretzel; Lois E Lamerato; Kayo Walsh; Heather M Rozjabek; Jerome Mabie; Brett Thomas; Tom Riley
Journal:  Prev Med       Date:  2014-07-16       Impact factor: 4.018

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.